Article
19 Mar 2026
Le CEPMB lance une consultation sur le projet de directives relatives à la pratique pour les audiences
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in Canada
AUTHORS CONTENT
Article
17 Mar 2026
PMPRB Launches Consultation On Proposed Practice Directions For Hearings
Article
29 Dec 2025
Les lignes directrices définitives du CEPMB sur le prix des médicaments brevetés entrent en vigueur le 1er janvier 2026 : ce que cela signifie pour les entreprises pharmaceutiques innovantes
Article
23 Dec 2025
Final Patented Medicines Pricing Guidelines From The PMPRB Take Effect On January 1, 2026: What This Means For Innovative Pharma
Article
04 Aug 2025
Aperçu du rapport statistique 2024-2025 de Santé Canada sur le régime canadien des brevets pharmaceutiques
Article
31 Jul 2025
Insights From Health Canada's 2024–2025 Statistical Report On Canadian Pharmaceutical Patent Regime
Article
20 Jun 2025
Biosimilar Update: Health Canada Reconsiders Requirement For Comparative Clinical Trials
Article
05 Jun 2025
Patent Re-Examination Board Decision Does Not Preclude Patent Validity Challenge In Court
Article
15 Apr 2025
Emergency Medicine: Innovations In Regulations For Public Health Drugs
Article
19 Dec 2024
Federal Court Of Appeal: Patented Medicine Prices Review Board "Crashed" Through "Guardrails" In Attempt To Regulate Unpatented Medicine
Article
03 Jun 2024
Damned If You Do, Damned If You Don't: Survey Evidence In Trade-Mark Cases
Article
10 May 2024
CADTH Is Now Canada's Drug Agency
Article
28 Mar 2024
Coming Soon: Updated Generic Submissions Under Review List
Article
11 Mar 2024
Canadian Pharmacare Legislation Has Arrived
Article
19 Oct 2021
The Canadian Patent Regime: A Complete Code
Article
24 May 2021
Eligibility For Supplementary Protection: The Federal Court Of Appeal Considers The Issue For The First Time
Article
05 May 2020
First Trial Decision Under Canada's Amended Patented Medicines (Notice Of Compliance) Regulations Offers Guidance On Key Issues